Abstract:Dendritic cells (DCs) play a pivotal role in initiating anti-tumor immune responses. Our group has developed an adoptive cellular transfer therapy (ACT) that significantly increases the infiltration of DCs and T cells into tumors, markedly enhancing survival in murine brain tumor models. However, tumors develop mechanisms to restrict the immune surveillance and the efficacy of immunotherapy, leading to tumor escape. In this study, we identified a mechanism involving DC dysfunction in ACT-escaped brain tumors. The finding that DCs are enriched after ACT treatment prompts an investigation into whether DC function is impaired in ACT-escaped tumors. Our results showed that DCs from both primary and ACT-escaped tumors were dysfunctional in their ability to activate T cells when co-cultured with tumor-reactive T cells or OT1 T cells. RNA-seq data revealed that, compared to primary tumor DCs, ACT-escaped tumor DCs exhibited a more pronounced reduction in conventional DC markers and antigen-presenting genes, alongside increased tolerance markers. Gene set enrichment analysis indicated that epithelial-mesenchymal transition (EMT) and hypoxia pathways were significantly enriched in ACT-escaped tumor DCs, suggesting divergent DC dysfunction mechanisms in primary versus escaped tumors. The anti-tumor role of DCs is primarily exerted through the activation of tumor-reactive T cells. Therefore, we assessed the cytotoxicity and exhaustion status of T cells in tumors. Surprisingly, we found that T cells from ACT-escaped tumors exhibited significantly higher levels of cytotoxicity and lower levels of T cell exhaustion compared to primary tumors. This suggests a T cell exhaustion-independent mechanism in ACT-escaped tumors. We further demonstrated that T cells in ACT-escaped tumor are mainly sourced from the adoptive transferred T cells, which recognize primary tumor antigens but not escaped tumor antigens. These results suggest that a combined mechanism of tumor antigen shifting and impaired DC function leads to a failure of antigen spreading and tumor eradication.

Biomechanical Alterations of Dendritic Cells by Co-Culturing with K562 CML Cells and Their Potential Role in Immune Escape.

[Biological features of dendritic cells derived from chronic myeloid leukemia cells in vitro].

The study of dendritic cells derived from acute myeloid leukemia cells]

[Effects of Imatinib Mesylate on the Development of Dendritic Cells Derived from Bone Marrow Mononuclear Cells of Patients with Chronic Myeloid Leukemia].

The Immunomodulatory Effects of Cordyceps Sinensis on Dendritic Cells Derived from Chronic Myelogenous Leukemia (Cml)

The Biological Characteristics of Dendritic Cells Derived in Vitro from Myelogeneous Leukemia Cells and Healthy Donor Cells.

Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton.

Alterations of Dendritic Cell Subsets in the Peripheral Circulation of Patients with Cervical Carcinoma.

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Biophysical Properties And Motility Of Human Mature Dendritic Cells Deteriorated By Vascular Endothelial Growth Factor Through Cytoskeleton Remodeling

Study on Immune Function of Dendritic Cells Derived from Chronic Myeloid Leukemia Cell Line in Vitro

Differentiation and Immunological Function of MDSC-Derived Dendritic Cells

Hepatocellular Carcinoma Cells Deteriorate the Biophysical Properties of Dendritic Cells

Effect of Dendritic Cells Co-Cultured with Cytokine Induced Killer Cells on Cytotoxicity Against Drug Resistant K562 Cells

Chapter Three - Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer

The role of dendritic cells in cancer immunity and therapeutic strategies

Transforming Growth Factor-Β1 Deteriorates Microrheological Characteristics and Motility of Mature Dendritic Cells in Concentration-Dependent Fashion.

Interleukin-10 Reorganizes The Cytoskeleton Of Mature Dendritic Cells Leading To Their Impaired Biophysical Properties And Motilities

Tumor Cells Evade Immunosurveillance by Suppressing Dendritic Cell Function

[Changes in the Immune Function of Dendritic Cells (DC) Derived from HBV-related Hepatocellular Carcinoma (HCC) Patient's Peripheral Blood Monocytes (PBMC) Pulsed with Tumor Antigen].

Tmic-09. Dendritic Cell Dysfunction Restricts Tumor Antigen Spreading In Adoptive Cellular Transfer Therapy-Escaped Gliomas: Implications For Tumor Immune Evasion